Therefore, the finding that TAAR1 stimulation through the β-arrestin2-dependent pathway leads to a silencing of GSK3β adds further support for the involvement of TAAR1 in schizophrenia and suggests that drugs that increase β-arrestin2 signaling by TAAR1 may be effective treatment for this disease. The gene discussed is GSK3B; the disease is schizophrenia.